3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione manufacturers
- Lenalidomide-5-Br
-
- $0.00 / 100mg
-
2026-04-22
- CAS:1010100-26-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione Basic information |
| Product Name: | 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione | | Synonyms: | 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione;2,6-Piperidinedione, 3-(5-bromo-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-;3-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;3-(5-Bromo-1-oxo-2-isoindolinyl)piperidine-2,6-dione;3-(5-bromo-1,3-dihydro-1-oxo-2h-isoindol-2-yl)-2,6-piperidinedione;Lenalidomide-5-Br;3-(5-bromo-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione;3-(5-bromo-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione | | CAS: | 1010100-26-1 | | MF: | C13H11BrN2O3 | | MW: | 323.14 | | EINECS: | | | Product Categories: | E3 ligase Ligan;E3 ligase Ligan | | Mol File: | 1010100-26-1.mol |  |
| | 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione Chemical Properties |
| Boiling point | 587.6±50.0 °C(Predicted) | | density | 1.688±0.06 g/cm3(Predicted) | | storage temp. | Storage temp. 2-8°C | | solubility | DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble) | | form | Solid | | pka | 10.60±0.40(Predicted) | | color | Off-white to gray | | InChI | InChI=1S/C13H11BrN2O3/c14-8-1-2-9-7(5-8)6-16(13(9)19)10-3-4-11(17)15-12(10)18/h1-2,5,10H,3-4,6H2,(H,15,17,18) | | InChIKey | CMRQAKJTXKOGSF-UHFFFAOYSA-N | | SMILES | N1C(=O)CCC(N2CC3=C(C2=O)C=CC(Br)=C3)C1=O |
| | 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione Usage And Synthesis |
| Description | 3-(5-Bromo-1-oxo-2-isoindolinyl)piperidine-2,6-dione is a lenalidomide analog that can be useful in PROTAC research because it is applicable to the recruitment of CRBN protein. | | Uses | Lenalidomide-5-Br is the Lenalidomide-based cereblon (CRBN) ligand used in the recruitment of CRBN protein. Lenalidomide-5-Br can be connected to the ligand for protein by a linker to form PROTAC[1]. | | IC 50 | Cereblon | | References | [1] Scheepstra M, et al. Bivalent Ligands for Protein Degradation in Drug Discovery. Comput Struct Biotechnol J. 2019;17:160-176. Published 2019 Jan 25. DOI:10.1016/j.csbj.2019.01.006
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. DOI:10.7554/eLife.57277 |
| | 3-(5-Bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione Preparation Products And Raw materials |
|